BioStock Investor Pitch: Saniona

Danish biopharma company Saniona has a broad drug development pipeline based on ion channel modulators. The company’s focus is on epilepsy, and candidate SAN711 leads the way with phase II evaluation in sights. Now Saniona is carrying out a rights issue of approximately SEK 140 million to drive SAN711 and other projects forward. Saniona’s CEO Thomas Feldthus visited BioStock’s studio to present the company and talk about the latest company updates.

Watch Saniona CEO Thomas Feldthus present the company in the BioStock Investor Pitch at biostock.se:

BioStock Investor Pitch: Saniona - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/